Market Overview

Eli Lilly Could Make A Lot More From Alzheimer's Drug Than Originally Thought

Share:
  • Eli Lilly and Co (NYSE: LLY) shares have gained 26 percent year-to-date, while still trading short of their 52-week high of $92.85.
  • Deutsche Bank’s Gregg Gilbert upgraded the rating on the company from Hold to Buy, while raising the price target from $85 to $99.
  • Solanezumab has the potential to impact the underlying course of Alzheimer’s Disease, Gilbert stated.

The peak estimate for solanezumab has been raised from ~$1B to ~$3B. Although the key Phase 3 read-out for sola is still about a year away, analyst Gregg Gilbert expects an increase in investor interest ahead of this event.

“Sola is by no means a cure for Alzheimer’s Disease (AD), but unlike current treatments it has the potential to affect the underlying course of the disease,” Gilbert wrote.

He explained that the current FDA-approved therapies for the diseases focused on symptomatic relief, and more than 20 million prescriptions had been written for them over the last year, despite limited clinical effect of these drugs. The existing market is US alone is estimated at $14B, applying brand pricing.

The market potential for novel products like solanezumab is about $27B in the US alone. “We do not expect sales to reach this level, but there seems to be room for several products with multi-billion dollar sales potential,” Gilbert commented.

The analyst is also excited about the prospects for the diabetes product Jardiance, which seems to be gaining momentum after the recent finding that the product improves cardiovascular outcomes.

Gilbert believes that management has “done a solid job stocking the pipeline with interesting late-stage development candidates,” and expects this to drive robust revenue and EPS growth in 2018 and beyond.

Latest Ratings for LLY

DateFirmActionFromTo
Oct 2019MaintainsBuy
Oct 2019ReinstatesBuy
Sep 2019ReiteratesNeutral

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Gregg GilbertAnalyst Color Long Ideas Upgrades Price Target Analyst Ratings Trading Ideas

 

Related Articles (LLY)

View Comments and Join the Discussion!

These Currency Hedged ETFs Could Enjoy 2016

Study Shows Lululemon Is Building Momentum; This Pro Is Selling Puts